Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis

The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week ther...

Full description

Saved in:
Bibliographic Details
Main Authors: M S Eliseyev, I S Denisov, Viktoria Georgiyevna Barskova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2012-03-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/400
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849303455723683840
author M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
author_facet M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
author_sort M S Eliseyev
collection DOAJ
description The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.
format Article
id doaj-art-37f720f7bdd8441c94375c07e3c2e4be
institution Kabale University
issn 1996-7012
2310-158X
language Russian
publishDate 2012-03-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-37f720f7bdd8441c94375c07e3c2e4be2025-08-20T03:59:57ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2012-03-0161444810.14412/1996-7012-2012-7151705Clinical experience with Uralyt-U used in patients with gout and nephrolithiasisM S EliseyevI S DenisovViktoria Georgiyevna BarskovaThe impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.https://mrj.ima-press.net/mrj/article/view/400gouturate nephrolithiasishyperuricemia
spellingShingle M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
Современная ревматология
gout
urate nephrolithiasis
hyperuricemia
title Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_full Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_fullStr Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_full_unstemmed Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_short Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_sort clinical experience with uralyt u used in patients with gout and nephrolithiasis
topic gout
urate nephrolithiasis
hyperuricemia
url https://mrj.ima-press.net/mrj/article/view/400
work_keys_str_mv AT mseliseyev clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis
AT isdenisov clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis
AT viktoriageorgiyevnabarskova clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis